Caplin Point Laboratories Limited
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and spray… Read more
Caplin Point Laboratories Limited - Asset Resilience Ratio
Caplin Point Laboratories Limited (CAPLIPOINT) has an Asset Resilience Ratio of 29.03% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Caplin Point Laboratories Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Caplin Point Laboratories Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹6.47 Billion | 18.47% |
| Short-term Investments | ₹3.70 Billion | 10.56% |
| Total Liquid Assets | ₹10.17 Billion | 29.03% |
Asset Resilience Insights
- Very High Liquidity: Caplin Point Laboratories Limited maintains exceptional liquid asset reserves at 29.03% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Caplin Point Laboratories Limited Industry Peers by Asset Resilience Ratio
Compare Caplin Point Laboratories Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Caplin Point Laboratories Limited (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Caplin Point Laboratories Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 11.54% | ₹3.70 Billion | ₹32.09 Billion | +0.90pp |
| 2024-03-31 | 10.64% | ₹2.87 Billion | ₹26.98 Billion | -33.45pp |
| 2023-03-31 | 44.09% | ₹9.66 Billion | ₹21.91 Billion | +19.27pp |
| 2022-03-31 | 24.82% | ₹4.31 Billion | ₹17.36 Billion | +11.50pp |
| 2021-03-31 | 13.32% | ₹1.82 Billion | ₹13.64 Billion | +3.53pp |
| 2020-03-31 | 9.79% | ₹1.10 Billion | ₹11.26 Billion | -6.23pp |
| 2019-03-31 | 16.02% | ₹1.19 Billion | ₹7.43 Billion | +2.51pp |
| 2018-03-31 | 13.51% | ₹675.99 Million | ₹5.00 Billion | +0.23pp |
| 2017-03-31 | 13.28% | ₹475.69 Million | ₹3.58 Billion | -5.73pp |
| 2016-03-31 | 19.00% | ₹507.58 Million | ₹2.67 Billion | +9.83pp |
| 2007-03-31 | 9.17% | ₹34.83 Million | ₹379.79 Million | -- |